The pTau 217 test was validated by the company using samples from Eli Lilly's Phase III TRAILBLAZER-ALZ 2 study, which ...

In cognitively healthy middle-aged adults at risk for Alzheimer’s disease, becoming physically active, especially in line ...

Alzheimer’s blood tests may one day allow patients and their doctors to track their individual progress in reducing risk, according to a new study.

A new blood test used to detect the pathology of Alzheimer’s Disease has just launched in Utah, and local experts are calling ...

dose-dependent reduction of amyloid plaques in the brain as measured by amyloid positron emission tomography. Trontinemab reduced amyloid levels below the 24 centiloid threshold in 81% of ...

In a comprehensive Genomic Press perspective article published today, researchers from Fudan University and Shanghai ...

dose-dependent reduction of amyloid plaques in the brain as measured by amyloid positron emission tomography (PET). Amyloid plaques are extracellular deposits of aggregated amyloid beta peptides ...

dose-dependent reduction of amyloid plaques in the brain as measured by amyloid positron emission tomography (PET). Trontinemab reduced amyloid levels below the 24 centiloid threshold in 81% of ...